Axinn Associates At The Antitrust Spring Meeting: Pharma Under The Antitrust Microscope

The Spring Meeting is the largest gathering of competition, consumer protection, and data privacy profes­sionals globally, with lawyers, academics, economists, enforcers, journalists, and students from around the world. During the Spring Meeting, Axinn associates attended thought leadership panels to capture key insights.

Axinn partner Lisl Dunlop moderated a panel entitled "Pharma Under the Antitrust Microscope," which outlined the legal and economic aspects of several new and emerging antitrust theories in the pharmaceutical industry. Key takeaways from the panel are below.

To read all the articles in the series, click here.

• Bundled Rebates. The panel highlighted a recent focus of the Federal Trade Commission (FTC) on the potential for large drug manufacturers to foreclose rivals and increase pricing through the practice of bundling rebates with Pharmacy Benefit Managers (PBMs), i.e., intermediaries who manage benefits and negotiate rebates with